Phosphoramidon inhibition of the in vivo conversion of big endothelin‐1 to endothelin‐1 in the human forearm
Open Access
- 1 September 1995
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 116 (2) , 1821-1828
- https://doi.org/10.1111/j.1476-5381.1995.tb16669.x
Abstract
1 The vasoconstrictor peptide, endothelin-1 (ET-1) and a biologically inactive C-terminal fragment (CTF) are generated from an intermediate big ET-1 by a putative ET converting enzyme, sensitive to phosphoramidon. We have developed a procedure using selective solid-phase extraction and specific radioimmunoassays to measure the levels of immunoreactive (IR) big ET-1 and the products of conversion (ET-1 and CTF) in human plasma. These techniques have been used to determine the levels of the three peptides in venous plasma following local infusions of ET-1 and big ET-1, both alone and together with phosphoramidon 2 Infusion of ET-1 into the brachial artery (5 pmol min−1) significantly increased (P−1 min−1 to 1.7 ml dl−1 min−1. The levels of IR big ET-1 and CTF were unchanged. Co-infusion of phosphoramidon (30 nmol min−1) with ET-1 had no significant effect on the plasma IR levels of ET, big ET-1, CTF, or blood flow 3 Big ET-1 (50 pmol min−1) significantly increased (P < 0.05) venous concentrations of all three IR peptides after 60 min compared to basal (ET: from 2.2 to 7.7 pM, big ET-1: from 0 to 386.0 pM, CTF: from 0.2 to 37.0 pM). Forearm blood flow decreased significantly (P < 0.05) from a basal level of 3.0 ml dl−1 min−1 to 1.6 ml dl−1 min−1 4 When phosphoramidon was co-infused with big ET-1, both the rise in IR ET and associated vasoconstriction were abolished. However, IR CTF was still detected, suggesting that either some conversion by phosphoramidon-insensitive enzyme(s) was occurring, and/or that CTF was being protected from further degradation by phosphoramidon 5 These data show that in the human forearm the activity of a phosphoramidon-sensitive ET converting enzyme is at least in part responsible for the vasoconstrictor properties of exogenous big ET-1. Furthermore, because measurable levels of newly synthesized ET-1 are likely to be rapidly reduced in the blood/plasma through receptor binding, assay of IR big ET-1 and CTF may be a more sensitive measure of ET-1 generation in disease.Keywords
This publication has 42 references indexed in Scilit:
- Molecular characterization of human and bovine endothelin converting enzyme (ECE‐1)FEBS Letters, 1994
- Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissueJournal Of Hypertension, 1992
- Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissuesBiochemical and Biophysical Research Communications, 1991
- Is Big Endothelin Converted to Endothelin-1 in Circulating Blood?Journal of Cardiovascular Pharmacology, 1991
- Phosphoramidon Blocks the Pressor Activity of Big Endothelin[1–39] and Lowers Blood Pressure in Spontaneously Hypertensive RatsJournal of Cardiovascular Pharmacology, 1991
- Inhibition of biological actions of big endothelin-1 by phosphoramidonBiochemical and Biophysical Research Communications, 1990
- Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzymeBiochemical and Biophysical Research Communications, 1990
- Distribution and molecular form of immunoreactive big endothelin-1 in porcine tissueBiochemical and Biophysical Research Communications, 1990
- Characterization of endothelin secretion by vascular endothelial cellsBiochemical and Biophysical Research Communications, 1990
- Analysis of endothelin related peptides in culture supernatant of porcine aortic endothelial cells: Evidence for biosynthetic pathway of endothelin-1Biochemical and Biophysical Research Communications, 1989